96709 ⎘
Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links; Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
Inhibitors of serine proteases
#302Hydrolysed Casein Product Comprising Tripeptides IPP and/or VPP
#303Antiviral compounds
#304Gene regulator
#305Macrocyclic Ghrelin Receptor Antagonists and Inverse Agonists and Methods of Using the Same
#306Skin aging-inhibiting peptide
#307Protease detection
#308Inhibitors of mammalian tight junction opening
#309Macrocyclic peptides as inhibitors of viral replication
#310Pharmaceutical compositions for prevention of overdose or abuse
#311ENZYMATIC CONJUGATION OF BIOACTIVE MOIETIES
#312Stabilized liquid enzyme compositions
#313Macrocyclic compounds as hepatitis C virus inhibitors
#314Macrocyclic cysteine protease inhibitors and compositions thereof
#315Novel Immunoregulatory Peptides, Compositions and Uses Thereof
#316Therapeutic compounds
#317Organic compounds and their uses
#318Substrate for assaying β-glucan and/or endotoxin and assay method
#319HCV NS3 protease inhibitors
#320Treatment of burns
#321Tertiary amine substituted peptides useful as inhibitors of HCV replication
#322METHODS AND COMPOSITIONS FOR INHIBITION OF MEMBRANE FUSION-ASSOCIATED EVENTS, INCLUDING HIV TRANSMISSION
#323Lipid tripeptide-based hydrogelator and hydrogel
#324SMAC mimetic compounds as apoptosis inducers
#325Derivatised proline containing peptide compounds as protease inhibitors
#326Compositions for the treatment or prophylaxis of viral infections
#327Macrolactone derivatives
#328PEPTIDES AND PEPTIDE MIMETICS TO INHIBIT THE ONSET AND/OR PROGRESSION OF FIBROTIC AND/OR PRE-FIBROTIC PATHOLOGIES
#329PEPTIDES AND PEPTIDE MIMETICS TO TREAT CANCER
#330IAP BIR DOMAIN BINDING COMPOUNDS
#331DRUG OR FOOD CONTAINING A PEPTIDE
#332SUBSTITUTED 1,2-ETHYLENEDIAMINES, METHODS FOR PREPARING THEM AND USES THEREOF
#333ORGANIC COMPOUNDS AND THEIR USES
#334Macrocyclic compounds as antiviral agents
#335HCV NS3 PROTEASE INHIBITORS
#336Compound having GPR54 agonistic activity
#337Hepatitis C virus inhibitors
#338Chemical linkers and cleavable substrates and conjugates thereof
#339Compounds for enzyme inhibition
#340Compounds for enzyme inhibition
#341Peptidomimetic protease inhibitors
#342Cyclic carboxamide compounds and analogues thereof as of hepatitis C virus
#343THERAPEUTIC ANTIVIRAL PEPTIDES
#344HCV NS3 Protease Inhibitors
#345SMAC Peptidomimetics and the Uses Thereof
#346NOVEL SMALL MOLECULE DNAK INHIBITORS
#347Inhibitors of Hepatitis C NS3 Protease
#348Hepatitis C Virus Inhibitors
#349HCV protease inhibitors and uses thereof
#350Selective Caspase Inhibitors
#351Hemiasterlin derivatives and uses thereof in the treatment of cancer
#352Peptides Inhibiting Angiotensin-Converting Enzyme
#353HCV protease inhibitors and uses thereof
#354HCV protease inhibitors and uses thereof
#355Carrier for separation, method for separation of compound, and method for synthesis of peptide using the carrier
#356Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors
#357Process for preparing macrocyclic compounds
#358Substituted 1,2-ethylenediamines, Methods for Preparing Them and Uses Thereof
#359Angiotensin-converting enzyme inhibitory peptides
#360Peptides having an ace inhibiting effect
#361Macrocyclic compounds as antiviral agents
#362HCV protease inhibitors and uses thereof
#363Peptides Having an Ace Inhibiting Effect
#364Hepatitis C virus inhibitors
#365AGENT FOR PREVENTING ARTERIOSCLEROSIS, AGENT FOR SUPPRESSING VASCULAR INTIMAL THICKENING AND AGENT FOR IMPROVING VASCULAR ENDOTHELIAL FUNCTION
#366MACROCYCLIC GHRELIN RECEPTOR ANTAGONISTS AND INVERSE AGONISTS AND METHODS OF USING THE SAME
#367Hepatitis C virus inhibitors
#368Hepatitis C virus inhibitors
#369MACROCYCLIC PEPTIDES ACTIVE AGAINST THE HEPATITIS C VIRUS
#370Liquid phase peptide synthesis of KL-4 pulmonary surfactant
#371Macrocyclic compounds as antiviral agents
#372Reagents and methods for smooth muscle therapies
#373Antiviral compounds
#374Selective substrates for matrix metalloproteinases
#375Boronic ester and acid compounds, synthesis and uses
#376Process for preparing peptide products for promoting cholecystokinin secretion and use of the peptide products
#377VASODILATOR
#378Methods and uses for protein breakdown products
#379Pharmaceutical salts of macrocyclic modulators of the ghrelin receptor
#380COMPOUNDS FOR ENZYME INHIBITION
#381Peptides that increase collagen or hyaluronic acid production
#382Compounds for enzyme inhibition
#383Difluorinated tripeptides as HCV serine protease inhibitors
#384Heteroaryl-containing tripeptide HCV serine protease inhibitors
#385Macrocyclic Modulators of the Ghrelin Receptor
#386Antiviral compounds
#387Reagents and Methods for Smooth Muscle Therapies
#388Reagents and methods for smooth muscle therapies
#389Methods of using macrocyclic modulators of the ghrelin receptor
#390Peptide inhibiting angiotensin converting enzyme
#391Biologically active C-terminal arginine-containing peptides
#392Macrocyclic tetrazolyl hepatitis C serine protease inhibitors
#393Spatially-defined macrocyclic compounds useful for drug discovery
#394Novel Nutraceutical Compositions
#395Process for preparing acyclic HCV protease inhibitors
#396Process for preparing acyclic HCV protease inhibitors
#397HCV NS3 protease inhibitors
#398Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
#399HCV PROTEASE INHIBITORS
#400TETRAZOLYL ACYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS
#401Protein hydrolysate enriched in peptides inhibiting DPP-IV and their use
#402HCV NS3 protease inhibitors
#403IMMUNOMODULATING OLIGOPEPTIDES
#404Method of producing peptide
#405Organic compounds
#4064-amino-4-oxobutanoyl peptides as inhibitors of viral replication
#407Antiviral compounds
#408Arylalkoxyl hepatitis C virus protease inhibitors
#409TETRAZOLYL ACYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS
#410ACYCLIC, PYRIDAZINONE-DERIVED HEPATITIS C SERINE PROTEASE INHIBITORS
#411INHIBITORS OF SERINE PROTEASE, PARTICULARLY HCV NS3-NS4A PROTEASE
#412Prodrug of an ICE inhibitor
#413Mimetic peptides and the use thereof in the form of 20S, 26S and immunoproteasome inhibitors
#414Antibody Binding Affinity Ligands
#415Antiviral Compounds
#416Immunoregulatory compositions
#417Peptidic compounds
#418PEPTIDES AND PEPTIDE MIMETICS TO TREAT PATHOLOGIES CHARACTERIZED BY AN INFLAMMATORY RESPONSE
#419C-Met receptor regulation by angiotensin IV (AT) receptor ligands
#420OXIMYL HYDROXYAMIC ANALOGS AS HEPATITIS C VIRUS PROTEASE INHIBITOR
#421Hydrazide-containing hepatitis C serine protease inhibitors
#422Conformationally constrained Smac mimetics and the uses thereof
#423Prion protein ligands and methods of use
#424N-FUNCTIONALIZED AMIDES AS HEPATITIS C SERINE PROTEASE INHIBITORS
#425Prodrug compounds with isoleucine
#426Thyrotropin-Releasing Hormone Analogs and Method of Use
#427Peptide compositions
#428Cytotoxic depsipeptides
#429Hiv Prodrugs Cleavable by Cd26
#430Biologically active peptides and their new uses
#431HCV PROTEASE INHIBITORS
#432IAP BIR domain binding compounds
#433ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS
#434Gene regulator
#435Treatment of burns
#436Hepatitis C virus inhibitors
#437Boronic ester and acid compounds, synthesis and uses
#438Antihypertensive Peptides
#439Inhibitors of Hepatitis C Virus
#440Isoquinoline derivatives as calpain inhibitors
#441ABUSE-RESISTANT HYDROCODONE COMPOUNDS, COMPOSITIONS AND METHODS OF USING THE SAME
#442IMMUNOREGULATORY COMPOSITIONS
#443IAP BIR domain binding compounds
#444Hemiasterlin derivatives and uses thereof in the treatment of cancer
#445Quinoxalinyl tripeptide hepatitis C virus inhibitors
#446Hepatitis C virus inhibitors
#447Synthetic methods for aplidine and new antitumoral derivatives, methods of making and using them
#448Compounds for enzyme inhibition
#449Compositions and methods for promoting myocardial and peripheral angiogenesis
#450Organic compounds and their uses
#451Boronic ester and acid compounds, synthesis and uses
#452Compounds and compositions as channel activating protease inhibitors
#453Tripeptide prodrug compounds
#454Prodrugs cleavable by CD26
#455Organic Compounds and Their Uses
#456Hepatitis C inhibitor compounds
#457Multi-location tractor trailer pneumatic connections
#458Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels
#459Nucleic acids encoding DP-178 and other viral fusion inhibitor peptides useful for treating aids
#460Antifusogenic proteins comprising human immunodeficiency virus type 1 (HIV-1) gp41 DP-178 polypeptide variants and a macromolecular carrier
#461Inhibitors of serine proteases
#462Tri-peptide hepatitis C serine protease inhibitors
#463Liquid phase peptide syntheses of KL-4 pulmonary surfactant
#464Tamandarin analogs and fragments thereof and methods of making and using
#465Inhibitors of hepatitis C virus NS3 protease
#466Compounds as inhibitors of hepatitis C virus NS3 serine protease
#467Deoxo-proline-containing tamandarin and didemnin analogs, dehydro-proline-containing tamandarin and didemnin analogs, and methods of making and using them
#468Combinatorial synthesis of libraries of macrocyclic compounds useful in drug discovery
#469Didemnin analogs and fragments and methods of making and using them
#470Compounds for enzyme inhibition
#471Cytotoxic depsipeptides
#472Antiviral compounds
#473Orally administered small peptides synergize statin activity
#474Anti-inflammatory peptides
#475Treatment of ischemic events
#476Hydrolysed casein product comprising tripeptides IPP and/or VPP
#477Molecules that block viral infectivity and methods of use thereof
#478Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission
#479HCV NS3 protease inhibitors
#480Methods of using macrocyclic modulators of the ghrelin receptor
#481Prodrug compounds with isoleucine
#482Hepatitis C virus inhibitors
#483Method of treating interferon non-responders using HCV protease inhibitor
#484Asymmetric dosing methods
#485Angiotensin-converting enzyme inhibitory peptides
#486Hepatitis C inhibitor peptide analogs
#487Substituted 1,2-ethylenediamines, methods for preparing them and uses thereof
#488Ace inhibitory peptides from plant materials
#489G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
#490Process for preparing macrocyclic compounds
#491Crystalline forms of (1R,2S)-N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenyl-cyclopropanecarboxamide, monopotassium salt
#492Aza-peptide epoxides
#493Hepatitis C virus inhibitors
#494Biologically active peptide conjugates
#495Pyrrolidine derivatives for use in treating heaptitis c virus infection
#496Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
#497Boronic ester and acid compounds, synthesis and uses
#498Antiviral compounds
#499Drug for preventing, regulating or treating adhesion
#500Streptavidin-binding peptide
#501Compounds for enzyme inhibition
#502Glycopeptide and peptide having a taste imparting function, and method of imparting the taste to foods
#503Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (IAP)
#504Acylsulfonamide compounds as inhibitors of hepatitis C virus NS3 serine protease
#505Neurotrophic and neuroprotective peptides
#506Reagents and methods for smooth muscle therapies
#507Cell adhesion inhibitors
#508Macrocyclic modulators of the ghrelin receptor
#509Granzyme b inhibitors
#510Liquid phase peptide synthesis of KL-4 pulmonary surfactant
#511Pharmaceutical compositions for prevention of overdose or abuse
#512Process for preparing acyclic HCV protease inhibitors
#513Inhibitors of hepatitis C virus NS3 protease
#514Hepatitis C virus inhibitors
#515Tri-peptide hepatitis C serine protease inhibitors
#516Propenoyl hydrazides
#517(1R,2S,5S)-N-[(1S)-3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[(2S)-2-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide as inhibitor of hepatitis C virus NS3/NS4a serine protease
#518Compounds as inhibitors of hepatitis C virus NS3 serine protease
#519Hemiasterlin derivatives and uses thereof
#520Piperidine compounds
#521Di-, tri-, and tetra-peptides having antiangiogenic activity
#522Gene regulatory peptides
#523Peptidomimetic protease inhibitors
#524Macrocyclic peptides active against the hepatitis C virus
#525Hepatitis C virus inhibitors
#526Selective substrates for matrix metalloproteinases
#527Orally administered small peptides synergize statin activity
#528Hepatitis C virus inhibitors
#529Compositions and methods for promoting myocardial and peripheral angiogenesis
#530Conformationally-controlled biologically active macrocyclic small molecules as motilin antagonists or ghrelin agonists
#531Method of removing transition metals
#532Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels
#533Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
#534Elastin peptide analogs and uses thereof
#535Somatostatin antagonists and agonists that act at the sst subtype 2 receptor
#536Combinatorial synthesis of libraries of macrocyclic compounds useful in drug discovery
#537Methods and uses for protein breakdown products
#538Hepatitis C inhibitor compounds
#539Peptide marker targeting to nasopharyngeal carcinoma cell and application thereof